BioSpace
Avsnitt

Why investors are taking another look at kidney disease

BioSpace
Dela

In this episode of Denatured, you’ll hear from Bruce Culleton, CEO at ProKidney and Demetri Maxim, CEO at Nephrogen. We discuss why kidney disease has long been a hard target for cell and gene therapies, and what new delivery strategies, therapeutic approaches and regulatory clarity mean for commercially viable products.

Host

Jennifer C. Smith-Parker, Director of Insights, BioSpace

Guests

Bruce Culleton, CEO, ProKidney

Demetri Maxim, CEO, Nephrogen

Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.

Rss Apple Podcaster
Podden och tillhörande omslagsbild på den här sidan tillhör BioSpace. Innehållet i podden är skapat av BioSpace och inte av, eller tillsammans med, Poddtoppen.